PRECLINICAL STUDY
Broad and Specific Caspase Inhibitor-Induced Acute Repression of Apoptosis in Atherosclerotic Lesions Evaluated by Radiolabeled Annexin A5 Imaging
Masayoshi Sarai, MD*,1,
Dagmar Hartung, MD*, ,1,
Artiom Petrov, PhD*,*,
Jun Zhou, MD*,
Navneet Narula, MD*,
Leo Hofstra, MD, PhD ,
Frank Kolodgie, PhD ,
Satoshi Isobe, MD*,
Shinichiro Fujimoto, MD*,
Jean-Luc Vanderheyden, PhD||,
Renu Virmani, MD, FACC ,
Chris Reutelingsperger, PhD ,
Nathan D. Wong, PhD*,
Sudhir Gupta, MD, PhD* and
Jagat Narula, MD, PhD, FACC*
* University of California, Irvine, California
Hannover Medical School, Hannover, Germany
University Hospital Maastricht, Maastricht, the Netherlands
International Registry of Pathology, Gaithersburg, Maryland
|| Theseus Imaging Corporation, Boston, Massachusetts.
Manuscript received April 10, 2007;
revised manuscript received August 23, 2007,
accepted August 24, 2007.
* Reprint requests and correspondence: Dr. Artiom Petrov, University of California, Irvine, School of Medicine, C116 Medical Science I, Irvine, California 92697. (Email: adpetrov{at}uci.edu).
Objectives: The purpose of this study was to evaluate the role of caspase inhibitors on acute resolution of apoptosis in atherosclerotic lesions as evaluated by imaging with annexin A5.
Background: Extensive apoptosis of macrophages has been reported at the site of plaque rupture in patients dying of acute coronary syndrome.
Methods: Of 31 New Zealand White atherosclerotic rabbits, 6 received broad caspase, 3 received caspase-1, 3 received caspase-3, 3 received caspase-8, and 4 received caspase-9 inhibitors; 12 animals did not receive any caspase inhibitors (treatment control group). Six unmanipulated rabbits were used for comparison (disease control group). Technetium-99m–labeled annexin A5 was used for imaging atherosclerotic lesions; 6 of the 12 uninhibited atherosclerotic rabbits received 99mTc-labeled mutant annexin A5 (radiotracer control group). Gamma images were obtained, and quantitative radiotracer uptake was compared with pathologic findings.
Results: Atherosclerotic lesions were best visible in untreated atherosclerotic rabbits. Quantitative annexin uptake, defined as the percent of injected dose per g of abdominal aorta tissue, was significantly higher in untreated atherosclerotic animals (mean ± SD = 0.0515 ± 0.0099) compared with the normal rabbits (0.0065 ± 0.0008; p < 0.0001) or atherosclerotic rabbits receiving mutant annexin (0.014 ± 0.0024; p < 0.0001). Among all caspase inhibitor-treated rabbits, uptake was 39% lower (0.0314 ± 0.0151) than in untreated atherosclerotic animals (p < 0.01). Uptake was also significantly lower in rabbits receiving broad caspase (0.0206 ± 0.0058; p < 0.0001) or caspase-1, -3, or -9 (0.0272 ± 0.0088, p < 0.01; 0.0286 ± 0.0095, p < 0.01; 0.0300 ± 0.0021, p < 0.01, respectively) inhibitors. Caspase-8 inhibitor did not affect apoptosis (0.0618 ± 0.0047; p = NS). Upon histologic characterization, a substantial decrease in macrophage apoptosis was observed in caspase-inhibited animals.
Conclusions: Molecular imaging, using radiolabeled annexin A5, allows the detection of acute resolution of apoptosis as a result of caspase inhibition in experimental atherosclerosis. If proven clinically, this may allow development of novel intervention strategies in acute vascular events.
|
Abbreviations and Acronyms
| | CT = computed tomography | | %ID/g = percent injected dose per gram | | PS = phosphatidylserine | | SPECT = single photon emission computed tomography | | TUNEL = terminal deoxyribonucleotide transferase-mediated nick-end labeling |
|
This article has been cited by other articles:

|
 |

|
 |
 
D. E. Sosnovik, M. Nahrendorf, P. Panizzi, T. Matsui, E. Aikawa, G. Dai, L. Li, F. Reynolds, G. W. Dorn II, R. Weissleder, et al.
Molecular MRI Detects Low Levels of Cardiomyocyte Apoptosis in a Transgenic Model of Chronic Heart Failure
Circ Cardiovasc Imaging,
November 1, 2009;
2(6):
468 - 475.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. P. Choudhury and E. A. Fisher
Molecular Imaging in Atherosclerosis, Thrombosis, and Vascular Inflammation
Arterioscler Thromb Vasc Biol,
July 1, 2009;
29(7):
983 - 991.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Laufer, M. H.M. Winkens, J. Narula, and L. Hofstra
Molecular Imaging of Macrophage Cell Death for the Assessment of Plaque Vulnerability
Arterioscler Thromb Vasc Biol,
July 1, 2009;
29(7):
1031 - 1038.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Sanz, P. R. Moreno, and V. Fuster
The year in atherothrombosis.
J. Am. Coll. Cardiol.,
April 14, 2009;
53(15):
1326 - 1337.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Tahara, T. Imaizumi, R. Virmani, and J. Narula
Clinical Feasibility of Molecular Imaging of Plaque Inflammation in Atherosclerosis
J. Nucl. Med.,
March 1, 2009;
50(3):
331 - 334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Osborn and F. A. Jaffer
The year in molecular imaging.
J. Am. Coll. Cardiol. Img.,
January 1, 2009;
2(1):
97 - 113.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nahrendorf, D. E. Sosnovik, B. A. French, F. K. Swirski, F. Bengel, M. M. Sadeghi, J. R. Lindner, J. C. Wu, D. L. Kraitchman, Z. A. Fayad, et al.
Multimodality Cardiovascular Molecular Imaging, Part II
Circ Cardiovasc Imaging,
January 1, 2009;
2(1):
56 - 70.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Narula and V. Dilsizian
From better understood pathogenesis to superior molecular imaging, and back...
J. Am. Coll. Cardiol. Img.,
May 1, 2008;
1(3):
406 - 409.
[Full Text]
[PDF]
|
 |
|
|